Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bachem Holding AGBCHMF 96 Cash-to-Debt is 0.25 as of Jun. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates BCHMF with a GF Score™ of 96/100 and a GF Value™ of $100.29 (Fairly Valued). The stock has 11 warning signs investors should review. Among 1,393 Biotechnology companies, Bachem Holding AG ranks better than 99.64% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Bachem Holding AG's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.25.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Bachem Holding AGcouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Bachem Holding AG's Cash-to-Debt or its related term are showing as below:
BCHMF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: No Debt Max: No Debt
Current: No Debt
During the past 13 years, Bachem Holding AG's highest Cash to Debt Ratio was No Debt. The lowest was 0.11. And the median was No Debt.
BCHMF's Cash-to-Debt is ranked better than 99.64% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs BCHMF: No Debt
Bachem Holding AG (OTCPK:BCHMF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Bachem Holding AG Cash-to-Debt Related Terms
Bachem Holding AG Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Bachem Holding AG's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BCHMF vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, Bachem Holding AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bachem Holding AG Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bachem Holding AG's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Bachem Holding AG's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bachem Holding AG (BCHMF) has a Cash-to-Debt of 0.25 as of Jun. 2026. This is 100% below median its historical median of 10,000.00. Over the past decade, Bachem Holding AG's Cash-to-Debt has ranged from 0.11 to 10,000.00. According to the industry distribution chart, Bachem Holding AG ranks #5 out of 1393 companies in the Biotechnology industry, placing it in the top 0.40000000000001%.
Is Bachem Holding AG's Cash-to-Debt too high?
Bachem Holding AG's current Cash-to-Debt of 0.25 is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.03. Bachem Holding AG's value of 0.25 is 96.4% below this industry median. Based on the distribution chart, Bachem Holding AG ranks #5 out of 1393 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bachem Holding AG has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bachem Holding AG's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bachem Holding AG ranks #5 out of 1393 companies for Cash-to-Debt. This places Bachem Holding AG in the top 0% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 7.03. Bachem Holding AG's value of 0.25 is 96.4% below this benchmark. Historically, Bachem Holding AG's own Cash-to-Debt has ranged from 0.11 to 10,000.00 over the past decade. While the company's 10-year median is 10,000.00 vs. the industry median of 7.03, Bachem Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bachem Holding AG's current Cash-to-Debt of 0.25 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bachem Holding AG's current Cash-to-Debt is 0.25, which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bachem Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Bachem Holding AG (BCHMF) is currently considered Fairly Valued. The stock's GF Value™ is $100.29, compared to a current price of $91.00 — trading 9.3% below its estimated fair value. The current Cash-to-Debt is 0.25, which is 100% below median its 10-year median of 10,000.00 and 96.4% below the Biotechnology industry median of 7.03. Bachem Holding AG's overall GF Score™ is 96/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Bachem Holding AG (BCHMF), the current Cash-to-Debt is 0.25 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bachem Holding AG (BCHMF) Overvalued in 2026?
Based on GuruFocus' analysis, Bachem Holding AG stock appears to be undervalued.
The current stock price of $91.00 is trading 9.3% below its estimated GF Value™ of $100.29.
GuruFocus considers Bachem Holding AG to be Fairly Valued.
Key valuation signals for BCHMF:
Cash-to-Debt: 0.25 (100% below median its 10-year median of 10,000.00)
GF Value™: $100.29 vs. price of $91.00 (9.3% below fair value)
Industry Position: 96.4% below the Biotechnology median (#5 of 1393)
No single metric tells the full story. See the BCHMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bachem Holding AG is a biochemical company that provides services to the pharmaceutical and biotechnology industry. It focuses on specializing in the development and manufacture of peptides and oligonucleotides. The group markets its products under the Bachem and Clinalfa brands. Its products and services are CMC Development, Commercial API, Research and Specialities, and Services and Capabilities. Geographically, it operates in Switzerland, USA, Ireland, Denmark, United Kingdom, and Rest of the World.
96GF Score
Get the complete analysis for BCHMF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCHMF has been successfully added to your 
